# US 2013/0274198 A1 · Treating muc1-expressing cancers with combination therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274198 A1
- Document ID: US20130274198A1
- Status: Published application
- Kind: A1
- Application number: 13/852,390
- Filed: 2013-03-28
- Published: 2013-10-17
- Earliest claimed: 2012-03-28
- Assignees: Dana-Farber Cancer Institute, Inc.; Genus Oncology, LLC
- Applicants: Dana-Farber Cancer Institute, Inc.; Genus Oncology, LLC.
- Inventors: DONALD KUFE; SURENDER KHARBANDA
- Web page: https://patentgrep.com/patent/US20130274198A1

## CPC

- A61K 38/03: Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/1735: {Mucins, e.g. human intestinal mucin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides method of treating cancers that express MUC1 by the administration of PI3-K inhibitors in combination with MUC1-directed cancer therapies. The PI3-K inhibition may advantageously be combined with peptides that inhibit MUC1 oligomerization, or further with other standard anticancer therapies such as chemo-, radio- and surgical therapies.

## Claims

### Claim 1

A method of inhibiting a cancer cell that expresses MUC1 comprising contacting said cancer cell with (a) an inhibitor of PI3-K and (b) a MUC1 peptide of at least 4 consecutive MUC1 residues and no more than 20 consecutive MUC1 residues and comprising the sequence CQC, wherein the amino-terminal cysteine of CQC is covered on its NH2-terminus by at least one amino acid residue that need not correspond to the native MUC-1 transmembrane sequence.

### Claim 2 (depends on 1)

The method of claim 1, wherein said cancer cell is metastatic, recurrent or multidrug resistant cancer cell.

### Claim 3 (depends on 1)

The method of claim 1, further comprising contacting said cancer cell with said PI3-K inhibitor more than once.

### Claim 4 (depends on 1)

The method of claim 1, further comprising contacting said cancer cell with said peptide more than once.

### Claim 5 (depends on 1)

The method of claim 1, further comprising contacting said cancer cell with said PI3-K inhibitor and said peptide more than once.

### Claim 6 (depends on 1)

The method of claim 1, wherein said PI3-K inhibitor is a PI3-K Class I inhibitor.

### Claim 7 (depends on 1)

The method of claim 1, wherein said PI3-K inhibitor is a PI3-K Class 1-selective or PI3-K Class I-specific inhibitor.

### Claim 8 (depends on 1)

The method of claim 1, wherein said cancer cell is a carcinoma cell, a leukemia cell or a myeloma cell.

### Claim 9 (depends on 7)

The method of claim 7, wherein the carcinoma cell is a prostate or breast carcinoma cell.

### Claim 10 (depends on 1)

The method of claim 1, wherein said peptide comprises at least 5, 6, 7 or 8 consecutive MUC residues, comprising CQCRRK (SEQ ID NO:4).

### Claim 11 (depends on 1)

The method of claim 1, wherein said peptide contains no more than 10 consecutive residues, 11 consecutive residues, 12 consecutive residues, 13 consecutive residues, 14 consecutive residues, 15 consecutive residues. 16 consecutive residues, 17 consecutive residues, 18 consecutive residues or 19 consecutive residues of MUC1.

### Claim 12 (depends on 1)

The method of claim 1, wherein said peptide is fused to a cell delivery domain.

### Claim 13 (depends on 12)

The method of claim 12, wherein said cell delivery domain is poly-D-R, poly-D-P or poly-D-K.

### Claim 14 (depends on 1)

The method of claim 1, wherein said peptide comprises all L amino acids or all D amino acids.

### Claim 15 (depends on 1)

The method of claim 1, wherein said peptide comprises a mix of L and D amino acids.

### Claim 16

A method of treating MUC1-expressing cancer cell in a subject comprising administering to said subject (a) an inhibitor of PI3-K and (b) a MUC1 peptide of at least 4 consecutive MUC1 residues and no more than 20 consecutive MUC1 residues and comprising the sequence CQC, wherein the amino-terminal cysteine of CQC is covered on its NH2-terminus by at least one amino acid residue that need not correspond to the native MUC-1 transmembrane sequence.

### Claim at position 17

17-30. (canceled)

### Claim 31 (depends on 16)

The method of claim 16, further comprising administering to said subject an additional anti-cancer therapy.

### Claim at position 19

32-37. (canceled)

### Claim 38 (depends on 16)

The method of claim 16, wherein inhibiting comprises inducing growth arrest of said cancer cell, apoptosis of said cancer cell and/or necrosis of a tumor tissue comprising said cancer cell.

### Claim at position 21

39-45. (canceled)

### Claim 46 (depends on 16)

The method of claim 16, further comprising, prior to administering, the step of assessing MUC1 expression in a cancer cell from said subject.

### Claim at position 23

47-48. (canceled)

### Claim 49

A kit comprising (a) a PI3-K inhibitor and (b) and MUC1 peptide of at least 4 consecutive MUC1 residues and no more than 20 consecutive MUC1 residues and comprising the sequence CQC, wherein the amino-terminal cysteine of CQC is covered on its NH2-terminus by at least one amino acid residue that need not correspond to the native MUC-1 transmembrane sequence.

### Claim 50

(canceled)
